ArticleAmerican journal of preventive cardiology2026
Low-density lipoprotein cholesterol longitudinal trajectories and clinical outcomes following an acute coronary syndrome.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate longitudinal low-density lipoprotein cholesterol (LDL-C) trajectories after acute coronary syndrome (ACS) and their association with clinical outcomes. Methods: We retrospectively studied 636 consecutive patients discharged after an ACS in a single-centre between 2018 and 2019 who had at least one outpatient LDL-C measurement after discharge. Associations between longitudinal LDL-C trajectories and mortality [cardiovascular (CV) and non-CV] or readmission for ACS were assessed using joint models. Results: The mean age was 69.2 ± 12.5 years, and 68.2% were male. Over a median follow-up of 5.8 years (IQR: 5.1-6.3), 6547 LDL-C measurements were recorded (median 14 per patient). Although LDL-C levels declined significantly over time ( Conclusion: After ACS, LDL-C levels decline over time, but achievement of guideline-recommended targets remains suboptimal. The adverse association between higher longitudinal LDL-C levels and CV mortality strengthens with longer follow-up, underscoring the importance of sustained long-term LDL-C control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.